Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3626856 | 0.97 | CHRM5 (0.33) | CYP2D6MEN1KMT2ALMNASLC18A3 | |
| SCHEMBL4175185 | 0.97 | CHRM5 (0.33) | CYP2D6MEN1KMT2ALMNASLC18A3 | |
| SCHEMBL13836053 | 0.97 | CYP2D6 (0.33) | CYP2D6MEN1KMT2ALMNASLC18A3 | |
| SCHEMBL27729 | 0.94 | — | — | |
| SCHEMBL3399160 | 0.92 | — | — | |
| SCHEMBL875158 | 0.91 | CHRNA7 (0.32) | CHRNA7 | |
| SCHEMBL13835555 | 0.89 | CYP2D6 (0.34) | CYP2D6MEN1KMT2ALMNACHRNA7 | |
| SCHEMBL24409361 | 0.88 | — | — | |
| SCHEMBL28564 | 0.88 | — | — | |
| SCHEMBL29941024 | 0.88 | CYP2D6 (0.31) | CYP2D6MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0530690-A2 | 1-Azabicycle(4,3,1)decane | BASF Aktiengesellschaft (DE) | 1993-03-10 | — | — | EP | claimed |
| EP-3281933-B1 | (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO LTD (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-10619058-B2 | Curable composition | TOAGOSEI CO., LTD. (JP) | 2020-04-14 | — | — | US | disclosed |
| US-10611856-B2 | Curable composition | TOAGOSEI CO., LTD. (JP) | 2020-04-07 | — | — | US | disclosed |
| EP-3133058-B1 | MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO LTD (JP) | 2019-05-29 | — | — | EP | disclosed |
| US-10266476-B2 | (Meth)acrylate manufacturing method | TOAGOSEI CO., LTD. (JP) | 2019-04-23 | — | — | US | disclosed |
| US-10065916-B2 | Method for producing (meth)acrylate | TOAGOSEI CO., LTD (JP) | 2018-09-04 | — | — | US | disclosed |
| US-20180237629-A1 | CURABLE COMPOSITION | TOAGOSEI CO., LTD. (JP) | 2018-08-23 | — | — | US | disclosed |
| US-10035752-B2 | Multifunctional (meth)acrylate manufacturing method | TOAGOSEI CO., LTD. (JP) | 2018-07-31 | — | — | US | disclosed |
| US-20180187026-A1 | CURABLE COMPOSITION | TOAGOSEI CO., LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-5834499-A | TREATING GASTROINTESTINAL DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| WO-1997035950-A1 | BLEACHING POWER ENHANCERS FOR BLEACHES AND TEXTILE WASHING COMPOSITIONS | BASF AKTIENGESELLSCHAFT (DE) | 1997-10-02 | — | — | WO | disclosed |
| EP-0749966-A1 | 5-HT 3 RECEPTOR AGONIST, NOVEL THIAZOLE DERIVATIVE, AND INTERMEDIATE THEREFOR | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-12-27 | — | — | EP | disclosed |
| EP-0530690-A3 | 1-AZABICYCLE(4,3,1)DECANE | BASF Aktiengesellschaft (DE) | 1993-04-28 | — | — | EP | disclosed |
| EP-0530690-A3 | 1-AZABICYCLE(4,3,1)DECANE | BASF Aktiengesellschaft (DE) | 1993-04-28 | — | — | EP | disclosed |
| EP-0530690-A2 | 1-Azabicycle(4,3,1)decane | BASF Aktiengesellschaft (DE) | 1993-03-10 | — | — | EP | disclosed |
| EP-0530690-A2 | 1-Azabicycle(4,3,1)decane | BASF Aktiengesellschaft (DE) | 1993-03-10 | — | — | EP | disclosed |
| EP-0530690-A2 | 1-Azabicycle(4,3,1)decane | BASF Aktiengesellschaft (DE) | 1993-03-10 | — | — | EP | disclosed |
| US-4267383-A | USING A COMPLEX CATALYST FROM A TRIARYL PHOSPHINE AND A RHODIUM CARBONYL HYDRIDE OR CHLORIDE | CELANESE CORPORATION (US) | 1981-05-12 | — | — | US | disclosed |
| US-4110404-A | Hydrocarbonylation | CELANESE CORPORATION (US) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065916-B2 | Method for producing (meth)acrylate | MMAB, ADH5, ADH1A | CYP2D6 957/4885MEN1 459/4885KMT2A 297/4885 |
| US-20180187026-A1 | CURABLE COMPOSITION | AZI2, KAT2A, KAT2B | CYP2D6 4844/4885MEN1 671/4885KMT2A 111/4885 |
| US-10035752-B2 | Multifunctional (meth)acrylate manufacturing method | MMAB, AMD1, ADH5 | CYP2D6 1416/4885MEN1 312/4885KMT2A 518/4885 |
| US-10611856-B2 | Curable composition | ACR, KAT2B, KAT5 | CYP2D6 4824/4885MEN1 195/4885KMT2A 279/4885 |
| US-10266476-B2 | (Meth)acrylate manufacturing method | MMAB, PAM, MAT2B | CYP2D6 2408/4885MEN1 57/4885KMT2A 535/4885 |
| US-10619058-B2 | Curable composition | ZMYND8, AZI2, KAT2A | CYP2D6 4854/4885MEN1 677/4885KMT2A 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.